- Meeting abstract
- Open Access
Severe ceftazidime-induced drug reaction with eosinophilia and systemic symptoms (DRESS)
Allergy, Asthma & Clinical Immunology volume 7, Article number: A37 (2011)
We describe a 55 years old female who developed DRESS with acute liver and kidney failure after being treated with ceftazidime and vancomycine. She was successfully treated with corticosteroids although while tapering prednisone she experienced a recurrence of the skin eruption without any systemic symptoms. She was taken off corticosteroids after 9 months of treatment.
In vitro tests
Fourteen months after the drug reaction, in vitro tests to identify the causal agent were performed. The lymphocyte transformation test (LTT) showed a marked proliferation to ceftazidime (stimulation index (SI): 17 at 100mcg/mL). CD25 was upregulated on CD4+ (induced expression: 17%) and CD8+ (induced expression: 8%) T cells as shown by flow cytometry when cultured with ceftazidime 50 mcg/mL. IFN-γ was markedly elevated in the supernatant of peripheral blood mononuclear cells (PBMC) cultured with ceftazidime 50 mcg/mL when compared to the control media (946 vs 13 pg/mL). Vancomycin did not induce a significant response when compared to the control media in the flow cytometry and the IFN-γ assays.
This is the first report of ceftazidime-induced DRESS to be subsequently proven by allergy tests. This case illustrates the importance of considering every susceptible drug as the potential etiologic agent. We also show the usefulness of in vitro tests in their identification.
Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011, 36: 6-11. 10.1111/j.1365-2230.2010.03967.x.
Pirmohamed M, Friedmann PS, Molokhia M: Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011, 89: 896-901. 10.1038/clpt.2011.79.
Kano Y, Shiohara T: The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009, 29: 481-501. 10.1016/j.iac.2009.04.007.